CAMP4 Therapeutics Corporation

NasdaqGM CAMP

CAMP4 Therapeutics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending November 30, 2023: -4.98%

CAMP4 Therapeutics Corporation EBIT Margin is -4.98% for the Trailing 12 Months (TTM) ending November 30, 2023, a 37.57% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

CAMP4 Therapeutics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending November 30, 2022 was -7.98%, a -146.21% change year over year.
CAMP4 Therapeutics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending November 30, 2021 was -3.24%, a 30.32% change year over year.
CAMP4 Therapeutics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending November 30, 2020 was -4.65%, a -373.10% change year over year.
CAMP4 Therapeutics Corporation EBIT Margin for the Trailing 12 Months (TTM) ending November 30, 2019 was 1.70%, a -40.48% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGM: CAMP

CAMP4 Therapeutics Corporation

CEO	Mr. Joshua Mandel-Brehm
IPO Date	Oct. 11, 2024
Location	United States
Headquarters	One Kendall Square Bldg 1400 West, 3rd Floor
Employees	58
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Key trends

Past 5 years